Sunshine Biopharma (NASDAQ:SBFM) Issues Earnings Results

Sunshine Biopharma (NASDAQ:SBFM) issued its quarterly earnings data on Thursday. The company reported ($1.15) EPS for the quarter, beating analysts’ consensus estimates of ($1.20) by $0.05, FiscalAI reports. The firm had revenue of $9.26 million for the quarter, compared to analyst estimates of $8.70 million. Sunshine Biopharma had a negative return on equity of 27.75% and a negative net margin of 18.45%.

Sunshine Biopharma Price Performance

NASDAQ:SBFM traded down $0.01 during trading hours on Thursday, reaching $1.20. 181,682 shares of the company were exchanged, compared to its average volume of 768,077. The company has a market capitalization of $601,200.00, a P/E ratio of -0.09 and a beta of 1.16. Sunshine Biopharma has a 1-year low of $1.10 and a 1-year high of $24.30. The business has a 50 day moving average of $1.87 and a 200 day moving average of $7.01.

Institutional Trading of Sunshine Biopharma

A number of institutional investors have recently modified their holdings of the stock. Virtu Financial LLC acquired a new stake in shares of Sunshine Biopharma during the 4th quarter worth $29,000. Two Sigma Investments LP acquired a new position in Sunshine Biopharma in the third quarter valued at about $32,000. Finally, Citadel Advisors LLC lifted its position in Sunshine Biopharma by 23.1% during the third quarter. Citadel Advisors LLC now owns 78,087 shares of the company’s stock worth $116,000 after purchasing an additional 14,656 shares during the period. 41.98% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently issued reports on SBFM shares. Zacks Research raised shares of Sunshine Biopharma to a “hold” rating in a research report on Wednesday, May 27th. Weiss Ratings lowered shares of Sunshine Biopharma from a “sell (e+)” rating to a “sell (e)” rating in a research report on Tuesday. One analyst has rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and an average target price of $70.00.

Sunshine Biopharma Company Profile

Sunshine Biopharma, Inc is a biotechnology company focused on the research, development and commercialization of novel drug candidates primarily for oncology. The company specializes in small-molecule therapeutics designed to overcome multidrug resistance and to target hard-to-treat cancers. Its preclinical pipeline emphasizes compounds that intercalate DNA and inhibit topoisomerase II, with the goal of advancing candidates into clinical trials for various solid tumors.

Among its lead programs, Sunshine Biopharma is advancing anthracycline-based compounds, including Bisantrene, which has demonstrated activity against breast and prostate cancer cell lines, and Adva-27a, a novel analog being evaluated for glioblastoma multiforme and other drug-resistant malignancies.